<DOC>
	<DOCNO>NCT00724984</DOCNO>
	<brief_summary>The first part study determine high dose study drug take without cause serious side effect patient lymphoma . The appropriate dose determine first part study use second part study assess disease response 2 different type lymphoma patient .</brief_summary>
	<brief_title>Study Safety Tolerability PCI-24781 Patients With Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<mesh_term>Abexinostat</mesh_term>
	<criteria>• age ≥ 18 year Phase I : Any measurable , histologically confirm , previously treat lymphoma Phase II : Measurable , histologically confirm , previously treat lymphoma one follow category : 1 . Follicular nonHodgkin 's Lymphoma 2 . Mantle cell lymphoma Ability swallow oral capsule without difficulty Estimated life expectancy &gt; 12 week ECOG performance status ≤ 1 Willing able sign write informed consent • More four prior systemic treatment regimen ( count maintenance rituximab ; salvage therapy/conditioning regimen precede autologous bone marrow transplantation [ ABMT ] ABMT count one regimen ) Allogeneic bone marrow transplant Immunotherapy , chemotherapy , radiotherapy experimental therapy within 4 week first day study drug dose Major surgery within 4 week first day study drug dose CNS lymphoma history meningeal carcinomatosis Prior treatment HDAC inhibitor ( unless treatment Mycosis fungoides Sézary syndrome ) Creatinine &gt; 1.5 x institutional upper limit normal ( ULN ) creatinine clearance ≤ 50 mL/min Total bilirubin &gt; 1.5 x institutional ULN ( unless elevate document Gilbert 's syndrome ) AST ALT &gt; 2.5 x institutional ULN Platelet count &lt; 75,000/µL Phase I &lt; 100,000 &gt; µL Phase II Absolute neutrophil count ( ANC ) &lt; 1500/µL Malabsorption Corticosteroids &gt; 20 mg prednisone equivalent per day ( topical , inhaled , nasal corticosteroid permit ) Concurrent therapeutic anticoagulation ( Phase I ) Uncontrolled illness include limited : ongoing active infection , symptomatic congestive heart failure ( New York Heart Association Class III IV heart failure ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness would limit compliance study requirement Risk factor , use drug know prolong QTc interval may associate QTc prolongation ( define QTc ≥ 450 msec ) significant ECG abnormality include 2nd degree AV block type II , 3rd degree AV block , bradycardia ( ventricular rate le 50 beats/min ) . If screen ECG QTc ≥ 450 msec , ECG submit centralize , cardiologic evaluation . History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty and/or stenting within past 6 month . For patient history myocardial infarction , congestive heart failure , abnormal leave ventricular ejection fraction ( LVEF ) , and/or prior anthracycline exposure , LVEF &lt; 50 % , assess ventriculography ( nuclear heart catheterization ) echocardiogram , perform within 28 day first dose study drug . For patient history coronary artery disease , cardiac stress test ( either exercise pharmacologic ) demonstrate clinically significant abnormality perform within 28 day first dose study drug . Known HIV infection . Other medical psychiatric illness organ dysfunction , opinion investigator , would either compromise patient 's safety interfere evaluation safety study agent . Pregnant lactate woman ( female patient childbearing potential must negative serum pregnancy test within 14 day first day drug dosing , , positive , pregnancy rule ultrasound ) . Women childbearing potential , sexually active men , unwilling use adequate contraceptive protection course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>PCI-24781</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Follicular</keyword>
	<keyword>Lymphoma , B-Cell , Marginal Zone</keyword>
	<keyword>Leukemia , Lymphocytic , Chronic , B-Cell</keyword>
	<keyword>Lymphoma , Mantle Cell</keyword>
	<keyword>Lymphoma , T-Cell , Cutaneous</keyword>
	<keyword>Lymphoma , T-Cell , Peripheral</keyword>
</DOC>